Loading
FIGS, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 08 Mar 2023.
FIGS, Inc.: what insiders have been doing
FIGS, Inc., founded in 2013, is a Healthcare & Pharma company based in Los Angeles, United States. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 22 filings came from 4 insiders.
Only sales appear on the open market, 10 sales in all totalling €2.9M, filed by 3 insiders. At €780k, the sale published on 6 April 2026 by Spear Catherine Eva is the largest of the period (0.041% of market cap).
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
With 22 filings in twelve months, the company is more active than the median of 19 filings across the 5,810 companies we follow on the same exchange. The full history, which starts in 2021, counts 4 purchases against 61 sales. The 10-K for the year ended 31 December 2025 shows 631.1 m USD of revenue and 34.3 m USD of net income.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
151
Thresholds
n/a
Buy Volume
€6M
4 ops. · all time
Sell Volume
€708M
61 ops. · all time
Who traded when
BuySaleHeather L. Hasson8 sales
Sarah Oughtred7 sales
Catherine Eva Spear4 sales
Since the insiders bought
- -12.2%Entry US$6.39 · Close at T+365 US$5.61
- -47.7%Entry US$13.23 · Close at T+365 US$6.92
- -59.4%Entry US$16.14 · Close at T+365 US$6.56
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,940 of 24,158 companies
56.1
score / 100
Value43
Quality69
FCF yld1.7%
Earn yld1.1%
EV/EBITDA·
ROE15%
Gross mgn67%
Net mgn5.4%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$18.63
Analyst consensus
8 analysts2.00/5
US$15.00Target US$18.63(-0%)US$22.00
Income statement
RevenueUS$631.1M
Gross profitUS$419.8M67% margin
EBITDAUS$47.2M7% margin
Net incomeUS$34.3M8.7% margin
Valuation
PER (trailing)56.5x
PER (forward)48.9x
P/Book7.0x
Beta1.07
Balance sheet & cash
Market capUS$3.1B
Total debtUS$60M
Free Cash FlowUS$53M
Debt / Equity13%
Profitability & ownership
ROE14.8%
ROA7.8%
% insiders4.5%
% institutions99.9%
Last declaration on 5 October 2026
Declarations151 total
22,196 shares@ US$14.080.014% mcap12.8% of flowClass A Common StockSEC:0001628280-26-065105:0
61,554 shares@ US$14.080.038% mcap6.0% of flowClass A Common StockSEC:0001628280-26-065107:0
6,812 shares@ US$14.080.0042% mcap0.6% of flowClass A Common StockSEC:0001628280-26-065103:0
21,962 shares@ US$10.920.012% mcap11.1% of flowClass A Common StockSEC:0001628280-26-054839:0
30,142 shares@ US$10.920.016% mcap2.1% of flowClass A Common StockSEC:0001628280-26-054847:0
6,813 shares@ US$10.050.0034% mcap0.4% of flowClass A Common StockSEC:0001628280-26-047413:0
61,556 shares@ US$10.050.031% mcap4.5% of flowClass A Common StockSEC:0001628280-26-047417:0
22,197 shares@ US$10.050.011% mcap10.4% of flowClass A Common StockSEC:0001628280-26-047419:0
15,456 shares0Class A Common StockSEC:0001628280-26-040592:0
23,597 shares@ US$14.33390.015% mcap15.4% of flowClass A Common StockSEC:0001628280-26-031588:0
32,385 shares@ US$14.33390.021% mcap2.9% of flowClass A Common StockSEC:0001628280-26-031586:0
10,872 shares@ US$14.43890.0072% mcap7.2% of flowClass A Common StockSEC:0001628280-26-023976:0
62,335 shares@ US$14.43890.041% mcap6.5% of flowClass A Common StockSEC:0001628280-26-023974:0
214,225 shares0Class A Common StockSEC:0001628280-26-015261:0
342,760 shares0Class A Common StockSEC:0001628280-26-015287:0
313,336 shares@ US$0.851.7% of flowClass A Common StockSEC:0001628280-26-014044:0
22,874 shares@ US$10.560.011% mcap1.5% of flowClass A Common StockSEC:0001628280-26-006583:0
22,690 shares@ US$10.560.011% mcap10.8% of flowClass A Common StockSEC:0001628280-26-006597:0
10,515 shares@ US$11.50040.0055% mcap5.5% of flowClass A Common StockSEC:0001628280-26-001435:0
49,734 shares@ US$11.37890.026% mcap4.0% of flowClass A Common StockSEC:0001628280-26-001432:0
22,745 shares@ US$7.38697.8% of flowClass A Common StockSEC:0001628280-25-050355:0
23,356 shares@ US$7.38691.1% of flowClass A Common StockSEC:0001628280-25-050351:0
62,213 shares@ US$6.88090.019% mcap3.0% of flowClass A Common StockSEC:0001628280-25-044385:0
9,968 shares@ US$7.360.0033% mcap3.3% of flowClass A Common StockSEC:0001628280-25-044387:0
947,868 shares0Class A Common StockSEC:0001843821-25-000004:0
25 of 151 declarations
About FIGS, Inc.
FIGS, Inc. is a United States-based company listed on the NYSE under the ticker FIGS, with headquarters in Santa Monica, California. Founded in 2013, the company has built a direct-to-consumer healthcare apparel brand focused on medical uniforms and related products for healthcare professionals. From an equity research perspective, FIGS stands out as a premium brand in a historically fragmented and underbranded category, where it has attempted to elevate scrubs from a commodity product into a design-led, technically differentiated offering.
The company’s business is organized around two primary product lines. The core category is scrubwear: medical workwear designed to meet the functional needs of clinicians while emphasizing comfort, durability, and style. The second category is non-scrubwear, which includes outerwear, underscrubs, footwear, compression socks, lab coats, loungewear, and other apparel. FIGS positions these offerings as an integrated system that serves healthcare professionals both on and off shift.
Read moreShow less
FIGS primarily sells through its digital direct-to-consumer platform, including its website and mobile app, which gives the company direct access to consumer demand, brand engagement data, and merchandising insights. It also operates physical “Community Hubs,” which function as brand experiences rather than a traditional wholesale retail footprint. In addition, the company has built TEAMS, a B2B channel aimed at hospitals, clinics, and other healthcare organizations.
Competitively, FIGS has carved out a strong position in premium healthcare apparel, supported by a well-known brand, a loyal customer base, and a product strategy that blends performance features with lifestyle positioning. The market remains competitive, however, with pressure from specialist apparel players and broader uniform brands. FIGS’ differentiators are its brand equity, direct customer relationship, in-house product development, and data-driven inventory and replenishment model. The company’s filings indicate a customer base of several million active customers and a business that remains heavily concentrated in the United States, although it also operates through FIGS Canada, Inc.
Recent highlights are important for investors. In early 2026, FIGS reported full-year 2025 results and said fourth-quarter net revenue rose sharply year over year, alongside better profitability metrics. Management also pointed to low double-digit revenue growth and margin expansion as objectives for fiscal 2026. For French-speaking investors, FIGS is best viewed as a specialty consumer-healthcare brand with exposure to healthcare employment trends, brand loyalty, and execution on growth, profitability, and merchandising discipline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
